What are the appropriate management recommendations for a patient with normal‑sized left ventricle, mildly increased wall thickness consistent with concentric hypertrophy, preserved ejection fraction, reduced global longitudinal strain, grade I diastolic dysfunction, trace mitral and tricuspid regurgitation, and a trivial pericardial effusion?

Management Recommendations for Concentric Hypertrophy with Preserved EF and Reduced GLS

This patient requires aggressive blood pressure control targeting <130/80 mmHg, investigation for the underlying cause of concentric hypertrophy (primarily hypertension), and close monitoring for progression to heart failure with preserved ejection fraction (HFpEF). 1

Immediate Diagnostic Workup

Identify the Underlying Etiology

The concentric hypertrophy pattern with grade I diastolic dysfunction strongly suggests hypertensive cardiomyopathy as the primary diagnosis 1. You must:

• Obtain detailed blood pressure history including home measurements and assess for uncontrolled or undertreated hypertension
• Rule out secondary causes of hypertension (renal artery stenosis, primary aldosteronism, pheochromocytoma) if BP is difficult to control
• Exclude aortic stenosis through careful auscultation and Doppler assessment of the aortic valve (already done if echo is complete)
• Consider infiltrative cardiomyopathies (amyloidosis, Fabry disease, sarcoidosis) if clinical features suggest these—though the normal cavity size and absence of "sparkling" myocardium make amyloid less likely 1

Assess for Early HFpEF

The reduced global longitudinal strain (GLS) of 16% is particularly concerning, as this represents subclinical systolic dysfunction despite the preserved ejection fraction of 59% 2, 3. Research demonstrates that concentric hypertrophy geometry is a significant independent determinant of impaired GLS 2, and this finding has important prognostic implications for progression to overt HFpEF 3.

Pharmacologic Management

Antihypertensive Therapy (Primary Intervention)

Optimize blood pressure control aggressively 4, 5:

• Target BP <130/80 mmHg (or even lower if tolerated)
• First-line agents: ACE inhibitors or ARBs are preferred given their beneficial effects on LV remodeling and regression of LV hypertrophy 5
• Add beta-blockers if heart rate is elevated or if there's evidence of increased sympathetic tone
• Consider aldosterone antagonists (spironolactone or eplerenone) particularly if there's evidence of volume retention or resistant hypertension
• Calcium channel blockers (non-dihydropyridine preferred) can be added for additional BP control and to improve diastolic function

Diastolic Dysfunction Management

For grade I diastolic dysfunction 5:

• Diuretics should be used cautiously and only if there's evidence of volume overload—these patients are preload-dependent
• Avoid excessive diuresis which can precipitate hypotension and reduced cardiac output
• Maintain sinus rhythm at all costs—atrial fibrillation would be poorly tolerated given the dependence on atrial contraction for ventricular filling 6

Monitoring and Follow-up

Serial Echocardiography

Repeat echocardiography in 6-12 months to assess 4, 7:

• LV mass regression with treatment (calculate LV mass index using height^2.7 for better accuracy in overweight patients)
• GLS trends—worsening strain despite preserved EF signals progression toward HFpEF 3
• Diastolic function progression—advancement from grade I to grade II/III indicates worsening disease
• Left atrial volume index—progressive LA enlargement predicts atrial fibrillation and adverse outcomes

Biomarker Surveillance

• BNP or NT-proBNP levels should be obtained as baseline and monitored—rising levels indicate progression even before symptoms develop 8
• Note that obesity can suppress natriuretic peptide levels, so interpret in clinical context 8

Lifestyle Modifications

Implement aggressive risk factor modification:

• Weight loss if BMI >25 kg/m²
• Sodium restriction to <2g/day
• Regular aerobic exercise (moderate intensity, 150 minutes/week)—avoid intense isometric exercise which can worsen hypertrophy
• Alcohol limitation to ≤1 drink/day for women, ≤2 for men
• Smoking cessation if applicable

Critical Pitfalls to Avoid

Do Not Dismiss the Reduced GLS

The most common error is focusing solely on the preserved EF of 59% and missing the reduced GLS of 16% 2, 3. This patient has subclinical systolic dysfunction that predicts progression to symptomatic HFpEF. The concentric hypertrophy geometry specifically predisposes to impaired GLS even when conventional measures appear normal 2.

Do Not Overlook the Trivial Pericardial Effusion

While described as "trivial," document this finding and reassess on follow-up imaging. Progressive effusion could indicate:

• Uremic pericarditis (check renal function)
• Inflammatory/autoimmune process
• Malignancy (though less likely with trivial amount)

Avoid Overdiuresis

Patients with concentric hypertrophy and diastolic dysfunction are exquisitely sensitive to preload reduction 6. Aggressive diuresis can precipitate hypotension, prerenal azotemia, and reduced cardiac output despite "normal" systolic function.

Prognosis and Patient Education

Counsel the patient that:

• Concentric LV hypertrophy carries increased cardiovascular risk even with preserved EF 4, 5
• The reduced GLS indicates early myocardial dysfunction requiring close monitoring 2, 3
• Strict BP control and medication adherence can promote LV mass regression and potentially prevent progression to symptomatic heart failure
• Symptoms to report immediately: dyspnea, orthopnea, paroxysmal nocturnal dyspnea, chest pain, palpitations, or syncope

When to Refer to Cardiology

Immediate cardiology referral if:

• Blood pressure remains uncontrolled despite 3-agent therapy
• GLS worsens on follow-up echocardiography
• Diastolic dysfunction progresses to grade II or III
• Patient develops symptoms (dyspnea, exercise intolerance, edema)
• New atrial fibrillation develops
• Pericardial effusion increases in size

The key principle: This is not a "normal" heart with trace findings—this represents early-stage hypertensive heart disease with subclinical dysfunction that requires aggressive intervention to prevent progression to overt HFpEF 4, 1, 2, 3.